Drug Profile
Research programme: glutamate racemase (MurI) inhibitors - AstraZeneca
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class
- Mechanism of Action Glutamate racemase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Gram-positive infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Gram-positive-infections in USA
- 02 Oct 2007 Early research in Gram-positive infections in USA (unspecified route)